Scholarlink

<p>Hepatocellular carcinoma (HCC) remains highly lethal, and emerging therapeutic strategies increasingly focus on harnessing ferroptosis to overcome treatment resistance. However, ferroptosis resistance has emerged as a major barrier to these approaches, highlighting the need to identify metabolic cues in the tumor microenvironment that drive this evasion. Here, we identify lactate as a critical metabolite that mediates detrimental metabolic crosstalk between HCC cells and hepatic stellate cells (HSCs), coupling this interaction to pyrimidine biosynthesis and enhanced extracellular matrix (ECM) production within the tumor microenvironment. We show that tumor-derived lactate activates mechanistic target of rapamycin complex 1 (mTORC1)–carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase (CAD) signaling, enhancing de novo pyrimidine biosynthesis and pre-ribosomal RNA synthesis, thereby promoting ECM protein translation. The resulting ECM deposition drives Yes-associated protein (YAP)/TEA domain family member (TEAD)-dependent upregulation of the cystine/glutamate antiporter (xCT) in HCC cells, conferring marked resistance to sorafenib-induced ferroptosis. Inhibition of dihydroorotate dehydrogenase, the rate-limiting enzyme in pyrimidine synthesis, disrupts ECM production and restores ferroptosis sensitivity in vitro and in vivo. Clinical data further support these findings, indicating that phosphorylated CAD (p-CAD) levels in HSCs are associated with both poor prognosis and lactate-associated ECM enrichment in HCC patients. Collectively, our study identifies lactate-fueled pyrimidine biosynthesis as a key driver of ECM remodeling and ferroptosis resistance in HCC. Targeting this metabolic axis offers a promising therapeutic strategy to overcome ECM-mediated drug resistance and improve outcomes with ferroptosis-based HCC therapies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Lactate-driven pyrimidine synthesis promotes ferroptosis resistance in hepatocellular carcinoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月17日

查看全文
  • Mun-Ju Park,
  • Sebin Lee,
  • Dong-Ho Kim,
  • Mi Kyung Kim,
  • Byoung Kuk Jang,
  • Ghilsuk Yoon,
  • Mihyang Park,
  • Gui-Hwa Jeong,
  • Jun-Kyu Byun,
  • Yeon-Kyung Choi,
  • Keun-Gyu Park

摘要

Hepatocellular carcinoma (HCC) remains highly lethal, and emerging therapeutic strategies increasingly focus on harnessing ferroptosis to overcome treatment resistance. However, ferroptosis resistance has emerged as a major barrier to these approaches, highlighting the need to identify metabolic cues in the tumor microenvironment that drive this evasion. Here, we identify lactate as a critical metabolite that mediates detrimental metabolic crosstalk between HCC cells and hepatic stellate cells (HSCs), coupling this interaction to pyrimidine biosynthesis and enhanced extracellular matrix (ECM) production within the tumor microenvironment. We show that tumor-derived lactate activates mechanistic target of rapamycin complex 1 (mTORC1)–carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase (CAD) signaling, enhancing de novo pyrimidine biosynthesis and pre-ribosomal RNA synthesis, thereby promoting ECM protein translation. The resulting ECM deposition drives Yes-associated protein (YAP)/TEA domain family member (TEAD)-dependent upregulation of the cystine/glutamate antiporter (xCT) in HCC cells, conferring marked resistance to sorafenib-induced ferroptosis. Inhibition of dihydroorotate dehydrogenase, the rate-limiting enzyme in pyrimidine synthesis, disrupts ECM production and restores ferroptosis sensitivity in vitro and in vivo. Clinical data further support these findings, indicating that phosphorylated CAD (p-CAD) levels in HSCs are associated with both poor prognosis and lactate-associated ECM enrichment in HCC patients. Collectively, our study identifies lactate-fueled pyrimidine biosynthesis as a key driver of ECM remodeling and ferroptosis resistance in HCC. Targeting this metabolic axis offers a promising therapeutic strategy to overcome ECM-mediated drug resistance and improve outcomes with ferroptosis-based HCC therapies.